Core Viewpoint - Rongchang Biopharma (09995) has seen its stock price increase by over 5%, currently trading at 90 HKD, following the acceptance of its RC288 injection application by NMPA, indicating strong market interest in its innovative drug pipeline [1] Group 1: Product Development - The RC288 injection, developed by Rongchang Biopharma, is a PSMA/B7H3 ADC that has demonstrated excellent anti-tumor activity and safety in preclinical studies [1] - The company is expected to enter a new growth phase starting in 2026, primarily driven by the launch of new indications for RC18, RC48, and RC28, which will also be included in medical insurance [1] Group 2: Future Revenue Streams - Sales from overseas indications for RC48 and RC18 are projected to begin in 2027, contributing to revenue through sales sharing agreements [1] - Starting in 2025, the company anticipates multiple asset licensing agreements, with upfront payments and milestones expected to enhance financial statements in the coming years [1] Group 3: Competitive Positioning - The newly entered global FIC pipeline, including CDCP1 ADC RC278 and B7H3/PSMA ADC RC288, holds potential global competitiveness and may lead to external licensing opportunities [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 JSKN021的IND申請獲CDE正式受理 本公告乃由康寧傑瑞生物製藥（「本公司」，連同其附屬公司，統稱「本集團」）自願 作出，以知會本集團股東（「股東」）及潛在投資者有關本集團之最新業務進展。 於2025年美國癌症研究協會年會發佈的臨床前數據顯示，JSKN021能有效抑制 HER3陽性、EGFR陽性或雙陽性腫瘤細胞的生長。此外，在多種CDX模型中， JSKN021的腫瘤抑制效果顯著優於單載荷ADC藥物。有關進一步詳情，請參閱本 公司日期為2025年4月30日的公告。 關於JSKN021 JSKN021是一款全球首創的雙抗雙載荷ADC，由靶向EGFR/HER3雙特異性抗體 與新型拓撲異構酶I抑制劑（「T01」）及甲基澳瑞他汀E（「MMAE」）偶聯而成。該 藥物通過精確調控雙抗結合親和 ...

Summary of Avicanna's Conference Call Company Overview - **Company Name**: Avicanna - **Stock Symbols**: OTCQX: AVCNF, TSX: AVCN - **Industry**: Life Sciences, specifically focusing on cannabinoid-based medical and pharmaceutical products Core Points and Arguments 1. **Company Background**: Avicanna started as a drug development company focused on treating unmet medical needs with evidence-based cannabinoid products, emphasizing a biotech and biopharma approach over the first five years of R&D [2][3] 2. **Target Markets**: The company targets medical indications such as pain, sleep, anxiety, dermatology, oncology, and neurological disorders, rather than the recreational cannabis market [3] 3. **Commercial Divisions**: Avicanna operates four commercial divisions: - Medical cannabis products providing standardized evidence-based products for specific clinical indications [4] - A medical cannabis platform (MyMedi) offering telemedicine and patient support [4] - A pharmaceutical pipeline focusing on advancing drug candidates based on insights from the medical cannabis platform [5] - A raw material division producing active pharmaceutical ingredients (APIs) in Colombia [5] 4. **RHO Phyto Brand**: This is Avicanna's flagship brand for non-inhaled evidence-based products, designed for specific delivery and dosing for various medical conditions [6][7] 5. **Insurance Coverage**: Approximately 80% of MyMedi patients benefit from insurance coverage, which includes partnerships with public and private payers [10] 6. **Pharmaceutical Pipeline**: The company is focused on four major drug candidates, including Trunerox, which has received marketing authorization in Colombia for Lennox-Gastaut syndrome [12][13] 7. **Clinical Trials**: Avicanna has initiated a Phase 2 clinical trial for osteoarthritic pain, funded by grants, with the potential for significant value creation if results are positive [14][35] 8. **Raw Material Division**: The company controls the quality of its active ingredients through its Colombian division, producing organic and sustainable biomass at a lower cost compared to competitors [15][16] 9. **International Expansion**: Avicanna aims to expand its operations internationally, leveraging its Canadian experience and proof-of-concept studies to enter new markets [18][33] 10. **Intellectual Property**: The company holds several patents and has a strong focus on protecting its intellectual property, which is seen as a significant asset as the industry matures [19][25] 11. **Market Positioning**: Avicanna is positioned as a serious medical cannabis company, differentiating itself from recreational cannabis firms, which has affected its stock market performance [21][22] 12. **Future Plans**: The company plans to focus on internationalization and the raw material opportunity, aiming to become a key supplier of APIs and a leader in cannabinoid drug delivery systems [32][34] Additional Important Content - **Collaborations**: Avicanna has established collaborations with leading academic and clinical institutions, enhancing its credibility and research capabilities [11][26] - **Market Challenges**: The company faces challenges related to market perception and stigma associated with cannabinoid products, impacting its stock price despite operational growth [22][38] - **Patient Education**: Avicanna emphasizes the importance of educating healthcare providers and patients about cannabinoid-based medicine to improve adoption and integration into standard care [40] - **Regulatory Environment**: The potential rescheduling of cannabis in the U.S. could open new opportunities for Avicanna, allowing for cross-border clinical development and research collaborations [41][42] This summary encapsulates the key points discussed during the conference call, highlighting Avicanna's strategic focus, market positioning, and future growth opportunities in the cannabinoid-based medical sector.

Group 1 - The company BeiGene (06160) announced that a total of 57,000 American Depositary Shares (ADS) will be purchased by 4,431 participants under the 2018 Employee Stock Purchase Plan during the subscription period from September 2, 2025, to February 27, 2026 [1] - The total number of shares involved in the purchase is 741,300, which represents approximately 0.05% of the total issued shares of the company as of the date of the announcement [1]

Financial Data and Key Metrics Changes - Total revenues grew by 15% in Q4 2025 and by 27% for the full year, reaching EUR 376.1 million [2][25] - Operating profit for 2025 was $26 million, a significant improvement from a loss in 2024 [2][28] - Operating cash flow was $55 million in 2025, with cash position at year-end above that of 2024 [3][28] - Adjusted operating profit was EUR 36.4 million, compared to a loss of EUR 8.6 million in 2024 [28] Business Line Data and Key Metrics Changes - RUCONEST revenue grew 26% year-over-year and 9% in Q4 2025, with U.S. volume growth of 20% [3][9] - Joenja revenue increased by 29% year-over-year and 53% in Q4 2025, reaching $19.8 million globally [4][12] - Joenja annual revenues exceeded EUR 50 million for the first time, triggering a EUR 5 million sales milestone payment [25] Market Data and Key Metrics Changes - Joenja's growth was fueled by new patient acceleration in the U.S. and increased demand in international markets, including the U.K. [4][14] - The number of identified APDS patients in the U.S. increased by 40 in 2025, more than double the increase in 2024 [14] Company Strategy and Development Direction - The company aims to maintain strong financial discipline while investing in growth drivers, focusing on becoming a leading rare disease company [6][8] - RUCONEST is positioned as a cornerstone treatment for severe HAE patients, while Joenja is expected to generate a significant portion of future revenues [32][34] - The company is exploring geographic expansion and regulatory approvals for Joenja, with a focus on pediatric indications [15][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth for RUCONEST and Joenja, with expectations for 2026 revenue between EUR 405 million and EUR 425 million [6][29] - The company anticipates operating expenses to increase at a slower pace, despite higher R&D investments [30] - Management highlighted the importance of upcoming clinical data readouts as potential value inflection points [32][34] Other Important Information - The company completed the enrollment of two leniolisib phase II trials and expects top-line data readout in the second half of 2026 [7][19] - The company is committed to optimizing capital allocations to support growth and shareholder value [8][30] Q&A Session Summary Question: Joenja growth expectations from U.S. vs. international markets - Management expects around 70%-75% of Joenja's growth in 2026 to come from the U.S. market [41][43] Question: RUCONEST patient return dynamics - Patients tend to return to RUCONEST quickly after trialing other treatments that do not control their crises effectively [37][38] Question: Timeline for getting patients on paid therapy in international markets - The company plans to submit pricing for reimbursement in Japan shortly, with launch timelines planned for summer [60][61] Question: Variants of uncertain significance (VUS) project timeline - New experiments are being planned, but timelines for results are not yet clear [76] Question: Inventory-related effects on RUCONEST sales - The company expects a higher inventory drawdown in Q1 due to market dynamics settling [78]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative price increase of over 20% in the next six months [15]. Core Insights - The company is enhancing its universal CAR-T product portfolio, with the in vivo CAR-T expected to initiate clinical trials in 2026. The proprietary platforms, THANK-uCAR® and THANK-u Plus®TM, are being utilized to develop differentiated universal CAR-T cell products [2][3]. - The company reported a revenue of 1.3 billion yuan in 2025, with a net loss of 1 billion yuan, a significant reduction from the previous year's loss of 8 billion yuan. As of December 31, 2025, cash and cash equivalents stood at 1.12 billion yuan [8]. - The company has received 218 orders for its product, Sikeizai®, from East China Pharmaceutical in 2025 and has been included in the "Commercial Health Insurance Innovative Drug Directory" [8]. Financial Projections - Revenue projections for the company are as follows: 2.6 billion yuan in 2026, 4.9 billion yuan in 2027, and 8 billion yuan in 2028, driven by the commercialization of CT053 and CT041 [10][11]. - The company anticipates a significant increase in net profit, projecting a profit of 63.26 million yuan in 2027 and 249.58 million yuan in 2028, following a net loss of 97.86 million yuan in 2025 [3][11]. - Earnings per share (EPS) are expected to improve from -0.17 yuan in 2025 to 0.43 yuan in 2028, reflecting the anticipated growth in profitability [3][11]. Product Development - The company is advancing multiple universal CAR-T products targeting various antigens, including CT0596 (BCMA) and CT1190B (CD19/CD20), with initial data expected to be presented at the ASH conference in December 2025 [2]. - The in vivo CAR-T candidate, KJ-C2529, targeting CD19/CD20 for B-cell lymphoma, is set to begin clinical trials in 2026 [2].

Core Viewpoint - Cathay Securities initiates coverage on Qianxin Biologics-B (02509) with a "Buy" rating, focusing on its development in immunology and allergy therapies, particularly in skin diseases, with a robust pipeline of products [1] Group 1: Market Potential - The global autoimmune drug market is projected to reach $176.7 billion by 2030, with biologics' share increasing from 72.8% in 2022 to 82.1% in 2030 [1] - The Chinese autoimmune market is expected to reach $19.9 billion by 2030, with a compound annual growth rate (CAGR) of 26.7% from 2025 to 2030, and biologics' share rising from 41.9% in 2022 to 69.3% in 2030 [1] Group 2: Product Pipeline and Collaborations - The company has a strong innovation pipeline in the autoimmune sector, with three dual-antibody pipelines expected to be licensed out by 2025, including exclusive rights for QX027N to Winddward Bio and significant licensing agreements with Roche and Caldera [2] - Domestic collaborations include commercial partnerships for QX001S and QX005N with East China Pharmaceutical, and agreements with leading domestic companies for other pipelines, enhancing market access and sales potential [2] Group 3: Financial Projections - EPS forecasts for the company are projected at 0.61, 0.42, and 0.83 yuan for the years 2025 to 2027, respectively, with a target price set at 30.15 HKD based on DCF valuation [1]

Core Viewpoint - The report from Guotai Junan Securities initiates coverage on Qianxin Biologics-B (02509) with a "Buy" rating, highlighting the company's focus on immunotherapy and allergy disease biotherapies, with a comprehensive pipeline targeting four major autoimmune diseases [1] Group 1: Company Overview - Qianxin Biologics is concentrating on immunotherapy for autoimmune and allergic diseases, prioritizing skin diseases in its product pipeline [1] - The company currently has one approved product, nine products in development, and over 20 IND-approved projects [1] Group 2: Market Potential - According to Frost & Sullivan, the global autoimmune drug market is expected to reach $176.7 billion by 2030, with the share of biopharmaceuticals increasing from 72.8% in 2022 to 82.1% in 2030 [1] - The Chinese autoimmune market is projected to reach $19.9 billion by 2030, with a compound annual growth rate (CAGR) of 26.7% from 2025 to 2030, and the share of biopharmaceuticals expected to rise from 41.9% in 2022 to 69.3% in 2030 [1] Group 3: Pipeline Progress - The company has demonstrated strong innovation capabilities in the autoimmune field, with plans to complete three dual-antibody pipelines for external licensing by 2025 [2] - The company has granted exclusive rights to Windward Bio for the overseas development and commercialization of QX027N (TSLPxIL-13 dual antibody) and has secured total licensing agreements of $1.07 billion with Roche and $555 million with Caldera for other dual antibodies [2] - In the domestic market, partnerships have been established with East China Pharmaceutical for QX001S (IL12/23p40) and QX005N (IL-4Rα), as well as collaborations with leading domestic pharmaceutical companies for further commercialization [2]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $46.4 million, a decrease of 6.9% compared to the same quarter in 2024 [12] - Procedure revenue declined 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million [12][13] - Gross profit margin was 68.0%, down from 71.8%, primarily due to a $1.3 million charge related to a voluntary recall [14] - Adjusted EBITDA decreased to $11.7 million with an adjusted EBITDA margin of 25.2%, compared to $15.1 million and 30.3% in the previous year [16] Business Line Data and Key Metrics Changes - Procedure revenue was primarily impacted by a lower number of net new clinic additions and lower procedure volume [12] - Dietary supplement revenue growth was driven by the continued expansion of the e-commerce channel [13] - The company anticipates dietary supplement revenue to grow at a mid- to high-single-digit rate in 2026 [14] Market Data and Key Metrics Changes - The company ended 2025 with over 90 salespeople, up from approximately 60 at the time of the sales reorganization [8] - The number of new Biote certified practitioners is a leading indicator of future procedure growth, with training sessions at full capacity [8] Company Strategy and Development Direction - The company aims to prioritize new clinic growth, maximize value from existing clinics, and strengthen accountability and discipline [6][9] - In 2026, the company plans to expand its sales personnel from over 90 to approximately 120 and invest in technology to enhance the practitioner experience [10][11] - The company is focused on operational excellence and improving internal processes to drive sustainable growth [9] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about re-accelerating procedure revenue growth and scaling the business more efficiently [9] - The company expects procedure revenue to decrease at a mid- to high-single-digit percentage rate in the first half of 2026, with a return to growth anticipated in the second half [17] - Planned investments in 2026 are expected to impact adjusted EBITDA but are seen as essential for long-term growth [11] Other Important Information - Cash flow from operations for 2025 was $35.2 million, with cash and cash equivalents at $24.1 million as of December 31, 2025 [16] Q&A Session Summary Question: Impact of FDA's removal of black box warnings for certain HRTs - Management views the removal as a positive tailwind, recognizing hormone optimization as a beneficial option for patients [21] Question: Details on the voluntary recall and FDA feedback - The company is working closely with the FDA and has received positive feedback regarding the recall process [22] Question: Procedure revenue growth in the first half of 2026 - The decline is attributed to higher attrition rates and lower volumes, with expectations for growth in the second half of 2026 [25][26] Question: Anticipated procedure revenue decline in Q1 versus Q4 - Management expects stabilization in attrition and monitoring of new customer growth, with a focus on the impact of the recall [30][33] Question: Clarification on EBITDA guidance - The decrease in EBITDA is primarily due to investments in sales personnel and technology to drive future growth [34][37] Question: Areas of focus for improving the tech platform - The company aims to enhance the practitioner experience through system improvements, both internally and with outside help [43][46] Question: Quarterly sales decline expectations for Q1 - Management anticipates a similar decline to Q4, with a focus on stabilizing attrition and monitoring recall impacts [48][49] Question: Current pellet supply through Asteria - The company is currently at about 50/50 on overall pellets being used from Asteria versus other providers, with plans to increase Asteria's share [52][56]

Vanda Pharmaceuticals Conference Call Summary Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on innovation to enhance people's happiness. The company has five approved products in the U.S. including: - **Fanapt**: An atypical antipsychotic for bipolar disorder and schizophrenia - **Hetlioz**: Approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome - **Ponvory**: Approved for multiple sclerosis - **NEREUS**: Recently approved for motion sickness - **Bysanti**: Approved for bipolar disorder and schizophrenia [2][3] Financial Position - Vanda ended the previous year with over **$260 million** in cash and no debt, indicating a strong financial position [3] - Revenue from Fanapt was **$117 million** in 2025, up from just under **$100 million** in 2024, with forecasts for **$150 million to $170 million** in 2026 [13][14] Product Pipeline and Growth Strategy - Vanda aims to grow and diversify revenue through existing products and new approvals, targeting **six approved products** by the end of the year [4] - Upcoming regulatory catalysts include: - **Imsidolimab**: BLA accepted for review with a PDUFA date of **December 12, 2026** [4] - **Bysanti**: Phase 3 study in major depressive disorder (MDD) with results expected by the end of 2026 [7][9] Bysanti's Market Potential - Bysanti's approval is expected to extend the revenue runway for Vanda's psychiatry portfolio, with potential label expansion for MDD [13][14] - The market size for schizophrenia and bipolar disorder is estimated at **10 million** patients, while MDD is approximately **20 million**, indicating significant growth potential [22] - Bysanti's pricing structure is expected to be more favorable than Fanapt, potentially leading to higher revenue [15][16] Commercialization Strategy - Vanda plans to leverage its existing psychiatry sales force for the launch of Bysanti in Q3 2026 [17][19] - The company anticipates that Bysanti could surpass Fanapt in demand due to its growth trajectory and market potential [20] NEREUS and Motion Sickness Market - NEREUS targets a market of **70 million** people in the U.S. experiencing motion sickness, with over **10 million** seeking treatment [51] - The product is expected to command premium pricing due to its favorable side effect profile compared to existing treatments [52] - Launch is anticipated in **mid-2026** [57] Research and Development Milestones - Vanda is focused on advancing its late-stage pipeline, including: - Phase 3 programs for NEREUS in GLP-1 market and Bysanti in MDD - Phase 3 for Fanapt long-acting injectable in schizophrenia [48] Regulatory Challenges - Vanda faced a Complete Response Letter (CRL) for NEREUS in gastroparesis but is pursuing a hearing with the FDA to present its case [78][80] - The company is optimistic about the potential for a favorable outcome based on recent legal victories [78] Future Outlook - Vanda's revenue guidance for 2026 is set at **$230 million to $260 million**, with specific targets for Fanapt, Ponvory, and Hetlioz [40][41] - The company is in an investment phase, expecting higher cash burn in 2026 due to product launches and pipeline investments [47] Conclusion - Vanda Pharmaceuticals is positioned for growth with a strong product pipeline and strategic focus on expanding its market presence in psychiatry and motion sickness. The company is navigating regulatory challenges while preparing for significant product launches in the near future.